# Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

> **NCT04278768** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Curis, Inc.** · enrollment: 366 (estimated)

## Conditions studied

- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Emavusertib
- **DRUG:** Venetoclax
- **DRUG:** Emavusertib

## Key facts

- **NCT ID:** NCT04278768
- **Lead sponsor:** Curis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-07-06
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 366 (ESTIMATED)
- **Why stopped:** Dosing completed in all cohorts. Planning underway for potential additional patient cohorts.
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04278768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04278768, "Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT04278768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*